Researchers at the 54th Annual American Society for Radiation Oncology meeting presented findings showing men with organ-confined prostate cancer can be treated successfully with stereotactic body radiation therapy.
To date, the study is the most extensive of its kind, with data from more than 1,000 patients treated for prostate cancer using the CyberKnife® technology. Low-risk, intermediate-risk and high-risk patients were evaluated for up to four years following treatment. At the five-year mark, the relapse-free survival rate was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients.
Patients who received SBRT in place of intensity-modulated radiation therapy also experienced fewer treatment sessions and expenses and fewer side effects.
Institutions such as Flushing Radiation Oncology, CyberKnife Center of Tampa Bay, CyberKnife Centers of San Diego, Swedish Medical Center, Georgetown University Hospital and UCLA Medical Center contributed patient data to complete the report, lead by author Dr. Alan Katz.
To learn more about results from this study, click here. To learn more about open clinical trials for prostate cancer at New Jersey CyberKnife, click here.